(Press-News.org) The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.
"The World Health Organization (WHO) estimated that more than 800,000 children younger than 5 years died from pneumococcal disease in 2000, making it the leading vaccine-preventable cause of death. Since the licensure in 2000 of the first 7-valent pneumococcal polysaccharide conjugate vaccine (PCV) for infants, many countries have added PCV to their existing national immunization programs. As a result, PCV immunization schedules differ between countries with respect to number of doses, age at vaccinations, and intervals between doses," according to background information in the article. "The optimal vaccine schedule for infants should provide maximal, sustained direct and indirect protection against invasive pneumococcal disease while using a minimal number of doses. The latter is particularly relevant in the context of overcrowded national immunization programs, public resistance to vaccines, and cost-effectiveness estimates."
Judith Spijkerman, M.D., of the University Medical Centre, Utrecht, the Netherlands, and colleagues compared immunogenicity of 4 different schedules using the 13-valent PCV (PCV13) to assess the optimal primary regimen with respect to antibody induction. The randomized clinical trial of healthy term infants in a general community in the Netherlands was conducted between June 2010 and January 2011, with 99 percent follow-up until age 12 months. Infants (n = 400) were randomly assigned (1:1:1:1) to receive PCV13 either at ages 2,4, and 6 months (2-4-6); at ages 3 and 5 months (3-5); at ages 2,3, and 4 months (2-3-4); or at ages 2 and 4 months (2-4), with a booster dose at age 11.5 months.
The researchers found that one month after the booster dose, there were no differences in IgG (Immunoglobulin G) geometric mean concentrations (GMCs) between the schedules for 70 of 78 comparisons. "The 2-4-6 schedule was superior to the 2-3-4 schedule for serotypes 18C and 23F and superior to the 2-4 schedule for serotypes 6B, 18C, and 23F. For serotype 1, the 3-5 schedule was superior to the 2-4-6, 2-3-4, and 2-4 schedules."
Secondary outcomes (GMCs measured 1 month after the primary series, at 8 months of age, and before the booster) demonstrated differences 1 month after the primary series. "The 2-4-6 schedule was superior compared with the 3-5, 2-3-4, and 2-4 schedules for 3,9, and 11 serotypes, respectively. Differences between schedules persisted until the booster dose," the authors write.
"To our knowledge, this is the first randomized controlled trial investigating immunogenicity of PCV13 in 4 different primary immunization schedules currently used in most high income countries. The primary outcome of this study, GMCs l month after the booster dose, showed that there were no statistically significant differences between the 4 schedules in IgG levels for most serotypes. However, differences between schedules were noted in secondary analyses. … Our findings demonstrate that optimal timing of the primary series, i.e., older age at vaccinations combined with longer intervals between vaccinations, is important to maintain optimal antibody levels during the period between the primary series and the booster dose."
"The choice of PCV schedule will require a balance between the need for early protection and maintaining protection between the primary series and the booster, in particular before herd effects offer clinical protection against vaccine serotype disease to as yet unvaccinated or incompletely vaccinated infants. When herd immunity is established, clinical relevance of the observed differences in immune responses may become of minor importance," the researchers conclude.
(doi:10.l001/jama.2013.228052; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: This study was performed by order and for the account of the Dutch Ministry of Health by additional immunization program research funding. Pfizer kindly provided 1,400 PCV13 vaccines. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Editorial: Optimizing the Use of Pneumococcal Conjugate Vaccine Globally
"A good deal remains to be learned about how best to use PCVs to protect the most vulnerable and the greatest number of community members," writes Katherine L. O'Brien, M.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, in an accompanying editorial.
"Immunogenicity is just one aspect of biological effect, perhaps more important for some serotypes than others. Focus should remain squarely on ensuring that every child is immunized with at least 3 doses of PCV, beginning early in life and administered in a timely fashion. The study by Spijkerman and colleagues reassures that PCV products now in use provide a robust immune response across a range of dosing schedules and focuses attention on specific serotypes of concern. It is good news that PCVs are adaptable to various dosing schedules and therefore to demands of vaccine programs across countries. Emphasis on immunogenicity differences should not be separated from the larger context of protection at the individual level, pneumococcal disease epidemiology, vaccine program performance, and ultimately clear measures of disease outcome."
(doi:10.l001/jama.2013. 228062; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of interest. Dr. O'Brien reported having received research grant support from GlaxoSmithKline and Pfizer and having served on external expert advisory groups related to pneumococcal vaccine for Merck, GlaxoSmithKline, and Aventis-Pasteur.
###
END
Children in a malaria-endemic community in Ghana who received a micronutrient powder with iron did not have an increased incidence of malaria, according to a study in the September 4 issue of JAMA. Previous research has suggested that iron supplementation for children with iron deficiency in malaria-endemic areas may increase the risk of malaria.
"In sub-Saharan Africa, malaria is a leading cause of childhood morbidity and mortality, and iron deficiency is among the most prevalent preventable nutritional deficiencies. The provision of iron to children with iron deficiency ...
"Hepatitis B virus (HBV) infection causes infant fulminant hepatitis (IFH), and chronic HBV infection may progress to chronic liver disease (CLD) and hepatocellular carcinoma (HCC). Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.
As reported ...
Washington, DC — Sleep increases the reproduction of the cells that go on to form the insulating material on nerve cell projections in the brain and spinal cord known as myelin, according to an animal study published in the September 4 issue of The Journal of Neuroscience. The findings could one day lead scientists to new insights about sleep's role in brain repair and growth.
Scientists have known for years that many genes are turned on during sleep and off during periods of wakefulness. However, it was unclear how sleep affects specific cells types, such as oligodendrocytes, ...
The use of whole bacterial genome sequencing will allow scientists to inexpensively track how bovine tuberculosis (TB) is transmitted from farm to farm, according to research presented this week at the Society of General Microbiology Autumn Conference.
Bovine TB is primarily a disease of cattle, caused by the bacterium Mycobacterium bovis. The disease is hugely expensive, costing the Government over £91 million in England in 2010/11.
Researchers from the University of Glasgow, working in collaboration with the Agri-Food and Biosciences Institute and the Department ...
People are much more likely to take preventive medicines if they're combined in one pill, an international study has found. The findings are published today in the Journal of the American Medical Association.
Taking aspirin, cholesterol-lowering and blood pressure-lowering drugs long-term more than halves heart attack and stroke recurrence. However, only about 50 per cent of people with cardiovascular disease in high-income countries take all recommended preventive medications. In low- and middle-income countries, only five to 20 per cent do. This leaves tens of millions ...
A study of around 5,000 older men has shown that stressful life events such as death of a loved one, or serious financial problems, significantly raised the risk of falls in the year following the incident. The research is published online today in the journal Age and Ageing.
Dr Howard A. Fink of the VA Medical Center in Minneapolis and colleagues conducted a study of 5,994 community-dwelling men over the age of 65 who were enrolled in the Osteoporotic Fractures in Men (MrOS) study in six locations across the United States. 5,125 participated in a second study visit ...
DURHAM, N.C. -- During a normal conversation, your brain is constantly adjusting the volume to soften the sound of your own voice and boost the voices of others in the room.
This ability to distinguish between the sounds generated from your own movements and those coming from the outside world is important not only for catching up on water cooler gossip, but also for learning how to speak or play a musical instrument.
Now, researchers have developed the first diagram of the brain circuitry that enables this complex interplay between the motor system and the auditory ...
New research from the University of East Anglia has shown that females can maximise the genetic quality of their offspring by being promiscuous.
Researchers studied red junglefowl (the wild ancestor of the domestic chicken) in a collaborative project with the University of Oxford, Stockholm University and Linköping University.
Findings published today in the journal Proceedings of the Royal Society B reveal that mating with different males helps females produce offspring that are more resistant to diseases.
This is down to 'cryptic female choice' -- where an internal ...
Frontiers in Physiology
Not a bat choice: echolocation works better than eyesight, even under adequate light
A new study in Frontiers in Physiology shows for the first time that bats catch insects by sonar as it is far more efficient than using vision, even during twilight.
Bats have eyes and may not have evolved their ultrasonic sonar from the earliest time of their existence on earth. Approximately 1000 species of bats use sonar to detect prey, despite showing considerable variation in the preferred size of their prey and their mode of hunting. But why? Many bats ...
Electronic devices with touchscreens are ubiquitous, and one key piece of technology makes them possible: transparent conductors. However, the cost and the physical limitations of the material these conductors are usually made of are hampering progress toward flexible touchscreen devices.
Fortunately, a research collaboration between the University of Pennsylvania and Duke University has shown a new a way to design transparent conductors using metal nanowires that could enable less expensive — and flexible — touchscreens.
The research was conducted by graduate student ...
